L11 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:619959 CAPLUS Full-text
DN 147:52917
TI method for treatment of an ocular neovascular disorder by administration of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide and (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid.
IN Brigandi, Richard Anthony; Levick, Mark; Miller, William Henry
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 49pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007064752	A2	20070607	WO 2006-US45776	20061129

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-740478P P 20051129

AB A method for treating an ocular neovascular disorder comprises administration of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methylbenzenesulfonamide (Pazopanib) and (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)- 2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or salts or solvates thereof. Pazopanib (multistep preparation given) in a mouse model reduced choroidal neovascularization in a dose-dependent manner.

IT 205678-26-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of ocular neovascular disorder by administration of dimethylindazolylmethylaminopyrimidinylaminomethylbenzenesulfonamide and oxopyridinylaminopropyloxytrifluoroethyltetrahydrobenzazepineacetate)

RN 205678-26-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 205676-70-6P
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(treatment of ocular neovascular disorder by administration of dimethylindazolylmethylaminopyrimidinylaminomethylbenzenesulfonamide and oxopyridinylaminopropyloxytrifluoroethyltetrahydrobenzazepineacetate)
RN 205676-70-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-2-methyl-3-oxo-, methyl ester (CA INDEX NAME)



IT 205676-79-5P 205676-80-8P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(treatment of ocular neovascular disorder by administration of dimethylindazolylmethylaminopyrimidinylaminomethylbenzenesulfonamide and oxopyridinylaminopropyloxytrifluoroethyltetrahydrobenzazepineacetate)
RN 205676-79-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205676-80-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 205676-69-3P 205676-71-7P 205677-80-1P
205677-81-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(treatment of ocular neovascular disorder by administration of dimethylindazolylmethylaminopyrimidinylaminomethylbenzenesulfonamide and oxopyridinylaminopropyloxytrifluoroethyltetrahydrobenzazepineacetate)
RN 205676-69-3 CAPLUS
CN Butanedioic acid, 2-[[4-methoxy-2-[(methylamino)methyl]phenyl]methyl]-, 1,4-dimethyl ester (CA INDEX NAME)



RN 205676-71-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-, methyl ester (CA INDEX NAME)



RN 205677-80-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-81-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1202261 CAPLUS Full-text
DN 145:495768
TI Soft tissue implants, anti-scarring agents, and therapeutic compositions
IN Hunter, William L.; Toleikis, Philip M.; Gravett, David M.; Maiti, Arpita; Liggins, Richard T.; Takacs-Cox, Aniko; Avelar, Rui; Signore, Pierre E.; Loss, Troy A. E.; Hutchinson, Anne; McDonald-Jones, Gaye; Lakhani, Fara
PA Angiotech International A.-G., Switz.
SO PCT Int. Appl., 2979pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006121521	A2	20061116	WO 2006-US11690	20060331
WO 2006121521	A3	20070111		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-679293P	P	20050510	
US 2005-679962P	P	20050510	

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

IT 205678-31-5, Sb-273005
RL: DEV (Device component use); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(soft tissue implants, anti-scarring agents, and therapeutic compns.)
RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1202260 CAPLUS Full-text
DN 145:495820
TI Electrical devices, anti-scarring agents, and therapeutic compositions
IN Hunter, William L.; Toleikis, Philip M.; Gravett, David M.; Maiti, Arpita; Liggins, Richard T.; Takacs-Cox, Aniko; Avelar, Rui; Signore, Pierre E.; Loss, Troy A. E.; Hutchinson, Anne; McDonald-Jones, Gaye; Lakhani, Fara
PA Angiotech International A.-G., Switz.
SO PCT Int. Appl., 2278pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006121518	A2	20061116	WO 2006-US11610	20060331
WO 2006121518	A3	20070111		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-679292P P 20050510
US 2005-679293P P 20050510

AB Elec. devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

IT 205678-31-5, Sb-273005
RL: DEV (Device component use); PAC (Pharmacological activity); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(implants incorporating anti-scarring agents)

RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:764538 CAPLUS Full-text
DN 145:262702
TI Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector
AU Popkov, Mikhail; Rader, Christoph; Gonzalez, Beatriz; Sinha, Subhash C.; Barbas, Carlos F., III
CS Department of Molecular Biology and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA
SO International Journal of Cancer (2006), 119(5), 1194-1207
CODEN: IJCNAW; ISSN: 0020-7136
PB Wiley-Liss, Inc.
DT Journal
LA English
AB Monoclonal antibody (mAb) 38C2 belongs to a group of catalytic antibodies that were generated by reactive immunization and contains a reactive lysine. 38C2 catalyzes aldol and retro-aldol reactions, using an enamine mechanism, and mechanistically mimics natural aldolase enzymes. In addition, mAb 38C2 can be redirected to target integrins αvβ3 and αvβ5 through the formation of a covalent bond between a β-diketone derivative of an arginine-glycine-aspartic acid (RGD) peptidomimetic and the reactive lysine residue in the antibody combining site to provide the chemical programmed mAb cp38C2. In this study, we investigated the potential of enhancing the activity of receptor-binding small mol. drug (SCS-873) through antibody conjugation. Using a M21 human melanoma xenograft model in nude mice, cp38C2 inhibited the growth of the tumor by .apprx.81%. The chemical programmed antibody was shown to be highly active at a low concentration while SCS-873 alone was ineffective even at dosages .apprx.1,000-fold higher than those used for the chemical programmed antibody. In vitro programming of the catalytic antibody was shown to be as effective as in vivo programming. In an exptl. metastasis assay, treatment with mAb cp38C2 significantly prolonged overall survival of tumor-bearing severe combined immuno-deficient (SCID) mice when compared to treatment with unprogrammed mAb 38C2, SCS-873 alone or the integrin-specific monoclonal antibody LM609. In vitro, cp38C2 inhibited human and mouse endothelial and human melanoma cell adhesion, migration and invasion. Addnl., cp38C2 inhibited human and mouse endothelial cell proliferation and was active in complement-dependent cytotoxicity assays. These studies establish the potential of chemical programmed monoclonal antibodies as a novel and effective class of immunotherapeutics that combine the merits of traditional small mol. drug design with immunotherapy.
IT 518315-49-6, SCS-873
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small mol. drug activity in melanoma models may be dramatically enhanced with an antibody effector)
RN 518315-49-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-[19-[[4-(3,5-dioxohexyl)phenyl]amino]-15,19-dioxo-4,7,10-trioxa-14-azanonadec-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:627654 CAPLUS Full-text
DN 145:89995
TI Methods and formulations of vitronectin antagonists to prevent scarring
IN Blake, Simon M.; Miller, William Henry; Sayani, Amyn; Wilkens, H. Jeffrey
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006069079	A2	20060629	WO 2005-US46204	20051220
WO 2006069079	A3	20070419		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2004-637824P P 20041221
OS MARPAT 145:89995
AB The present invention describes methods and formulations using vitronectin receptor antagonists for the prevention of excessive scarring.
IT 205678-16-6
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(methods and formulations of vitronectin antagonists to prevent scarring)
RN 205678-16-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



L11 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:219703 CAPLUS Full-text
DN 142:274008
TI Methods for treating rheumatoid arthritis by administration of humanized antibody to IP-10 alone or in combination with additional therapeutic agents
IN Lane, Thomas E.
PA USA
SO U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005053600	A1	20050310	US 2004-938673	20040909
WO 2005023201	A2	20050317	WO 2004-US29373	20040909
WO 2005023201	A3	20050609		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-501312P P 20030909

AB The invention discloses methods and compns. for treating rheumatoid arthritis through the administration of humanized anti-IP-10 antibody alone or in combination with an addnl. anti-rheumatic therapeutic compound Early treatment of type II collagen-induced mouse arthritis models with anti-IP-10 monoclonal antibody IP6C7 remarkably diminished paw swelling.

IT 205678-31-5, SB273005
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as addnl. agent; humanized antibody to IP-10 alone or in combination with addnl. therapeutic agents for treating rheumatoid arthritis)

RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:902129 CAPLUS Full-text
DN 141:388640
TI Nitrogen containing integrin targeting compounds
IN Tamiz, Amir; Bradshaw, Curt W.
PA Covx Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091542	A2	20041028	WO 2004-US12034	20040415
	WO 2004091542	A3	20050414		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-463456P P 20030415
US 2003-507887P P 20030930
OS MARPAT 141:388640
AB The present invention provides integrin targeting compds. which comprise small mol. weight integrin targeting agent-linker conjugates which are linked to a polymer such as a protein. The integrin targeting compds. of the invention comprise an RGD peptidomimetic integrin targeting agent covalently linked to a polymer such as the combining site of an antibody. Various uses of the invention compds. are provided, including methods to prevent or treat cancer or other disease.
IT 518315-49-6D, conjugates with mouse monoclonal 38C2 antibody
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrogen containing integrin targeting compds. linked to polymers such as proteins and antibodies for treatment of cancer and other diseases)
RN 518315-49-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-[19-[[4-(3,5-dioxohexyl)phenyl]amino]-15,19-dioxo-4,7,10-trioxa-14-azanonadec-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)



PAGE 1-B



IT 782475-44-9D, conjugates with mouse monoclonal 38C2 antibody
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrogen containing integrin targeting compds. linked to polymers such as proteins and antibodies for treatment of cancer and other diseases)

RN 782475-44-9 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-[(16S)-16-[[4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]amino]-39-[[4-(3,5-dioxohexyl)phenyl]amino]-15,19,35,39-tetraoxo-4,7,10,24,27,30-hexaoxa-14,20,34-triazanonatriacont-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



Appl's

L11 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:878370 CAPLUS Full-text
DN 141:366143
TI Preparation of alkoxyoxobenzazepinylacetates from the corresponding phenols prepared in turn from formylhydroxyphenylmethylidenesuccinates
IN Conde, Jose J.; Goldfinger, Lewilynn L.; Mcguire, Michael A.; Shilcrat, Susan C.; Wallace, Michael D.; Yu, Marvin Sungwhan
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004089890	A2	20041021	WO 2004-US9909	20040329
WO 2004089890	A3	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1628949	A2	20060301	EP 2004-758669	20040329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2006522139	T	20060928	JP 2006-509533	20040329
US 2006194786	A1	20060831	US 2005-551710	20051003
PRAI US 2003-460535P	P	20030404		
US 2004-546212P	P	20040220		
WO 2004-US9909	W	20040329		

OS MARPAT 141:366143
GI



I



II



III





AB Title compds. [I; R1 = Q5, Q6, etc.; R2 = haloalkyl, (substituted) alkyl, alkenyl, alkynyl, oxoalkenyl, oxoalkynyl, aminoalkyl, aminoalkenyl, etc.; W = (CHRg)aU(CHRg)b; a, b = 0-2; m, n = 0, 1; Q1-Q4 = N, CRy; ≤1 of Q1-Q4 = N; Ry = H, halo, cyano, NO2, CF3, (substituted) alkyl, etc.; U = null, CO, O, NRg, CO2, N:N, C.tplbond.C, etc.; Rg = H, alkyl, cycloalkylalkyl, aralkyl, heterocyclylalkyl; R' = H, alkyl, aralkyl, cycloalkylalkyl; R'' = R', COR',

CO2R'], were prepared from benzazepine-phenols (II; R2 as above; R3 = H, protecting group), which in turn were prepared from formylhydroxyphenylmethylidenesuccinates (III; R4, R5 = H, protecting group). Thus, Me [(S)-8-hydroxy-3-oxo-2-(2,2,2- trifluoroethyl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-4-yl]acetate (preparation given) in tert-Bu Me ether (TBME) was treated with 6-methylamino-2- pyridineethanol (preparation given) in TBME followed by Ph3P and diisopropyl azodicarboxylate in TBME under cooling followed by stirring at room temperature to give after saponification with LiOH 56% (S)-(-)-8-[2-[6-(methylamino)pyridin-2- yl]-1-ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-1,2,4,5-tetrahydro-2- benzazepine-4-acetic acid.

IT 205678-16-6P 205678-26-8P 205678-31-5P
779349-64-3P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)(preparation of alkoxyoxobenzazepinylacetates from the corresponding phenols prepared in turn from formylhydroxyphenylmethylidenesuccinates)

RN 205678-16-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 205678-26-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 779349-64-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



IT 205677-02-7P 205677-04-9P 205677-32-3P
773059-56-6P 779349-60-9P 779349-63-2P
779349-65-4P, Methyl 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetate 779349-67-6P
779349-68-7P 779349-69-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(preparation of alkoxyoxobenzazepinylacetates from the corresponding phenols prepared in turn from formylhydroxyphenylmethylidenesuccinates)

RN 205677-02-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205677-04-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205677-32-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 773059-56-6 CAPLUS
CN Butanedioic acid, [(2-formyl-4-hydroxyphenyl)methyl]-, dimethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 779349-60-9 CAPLUS
CN Butanedioic acid, [[2-(dimethoxymethyl)-4-hydroxyphenyl]methyl]-, (2S)-, compd. with N-cyclohexylcyclohexanamine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 779349-59-6
CMF C14 H18 O7

Absolute stereochemistry.



CM 2

CRN 101-83-7
CMF C12 H23 N



RN 779349-63-2 CAPLUS
CN Butanedioic acid, [[2-[[[(1,1-dimethylethoxy)carbonyl](2,2,2-trifluoroethyl)amino]methyl]-4-methoxyphenyl]methyl]-, (2S)-, compd. with N-cyclohexylcyclohexanamine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 779349-62-1
CMF C20 H26 F3 N O7

Absolute stereochemistry.



CM 2

CRN 101-83-7
CMF C12 H23 N



RN 779349-65-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 779349-67-6 CAPLUS
CN Butanedioic acid, [[2-(dimethoxymethyl)-4-hydroxyphenyl]methyl]-, compd.

with N-cyclohexylcyclohexanamine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 779349-66-5
CMF C14 H18 O7



CM 2

CRN 101-83-7
CMF C12 H23 N



RN 779349-68-7 CAPLUS
CN Butanedioic acid, [(2-formyl-4-hydroxyphenyl)methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 779349-69-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester (9CI) (CA INDEX NAME)



L11 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:811010 CAPLUS Full-text
DN 142:23498
TI Chemical Adaptor Immunotherapy: Design, Synthesis, and Evaluation of Novel Integrin-Targeting Devices
AU Li, Lian-Sheng; Rader, Christoph; Matsushita, Masayuki; Das, Sanjib; Barbas, Carlos F., III; Lerner, Richard A.; Sinha, Subhash C.
CS Skaggs Institute for Chemical Biology, Department of Molecular Biology, Scripps Research Institute, La Jolla, CA, 92037, USA
SO Journal of Medicinal Chemistry (2004), 47(23), 5630-5640
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 142:23498
AB A series of β-diketone derivs. of RGD peptidomimetics that selectively bind to αvβ3 and αvβ5 integrins were synthesized and covalently docked to the reactive lysine residues of monoclonal aldolase antibody 38C2. The resulting targeting devices strongly and selectively bound to human cancer cells expressing integrins αvβ3 and αvβ5 as analyzed by flow cytometry. In vitro and in vivo studies revealed that these novel integrin-targeting devices efficiently inhibit tumor growth. Thus, the combination of β-diketone derivs. of RGD peptidomimetics that target cell surface integrins αvβ3 and αvβ5 with monoclonal aldolase antibodies through formation of a covalent bond of defined stoichiometry holds promise as a new approach to cancer therapy.
IT 801239-98-5
RL: PRP (Properties)
(mol. docking studies of RGD peptidomimetics binding integrin αvβ3)
RN 801239-98-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 518315-49-6P 801239-17-8P 801239-19-0P
801239-22-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of diketone derivs. of RGD peptidomimetics as antitumor agents and determination of their biol. activity towards integrins αvβ3 and αvβ5)
RN 518315-49-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-[19-[[4-(3,5-dioxohexyl)phenyl]amino]-15,19-dioxo-4,7,10-trioxa-14-azanonadec-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 801239-17-8 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-[15,19-dioxo-19-[[4-[3-oxo-3-(2-oxocyclohexyl)propyl]phenyl]amino]-4,7,10-trioxa-14-azanonadec-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 801239-19-0 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-[19-[[4-(3,5-dioxohexyl)phenyl]amino]-15,19-dioxo-4,7,10-trioxa-14-azanonadec-1-yl]-2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 801239-22-5 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-[19-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-15-oxo-4,7,10-trioxa-14-azanonadec-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 801239-28-1P 801239-30-5P 801239-84-9P
801239-85-0P 801239-86-1P 801240-04-0P
801240-05-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of diketone derivs. of RGD peptidomimetics as antitumor agents and determination of their biol. activity towards integrins αvβ3 and αvβ5)

RN 801239-28-1 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-(17,17-dimethyl-15-oxo-4,7,10,16-tetraoxa-14-azaoctadec-1-yl)-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 801239-30-5 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 8-[2-[6-[[(1,1-dimethylethoxy)carbonyl]methylamino]-2-pyridinyl]ethoxy]-2-(17,17-dimethyl-15-oxo-4,7,10,16-tetraoxa-14-azaoctadec-1-yl)-2,3,4,5-tetrahydro-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 801239-84-9 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 8-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-2-(17,17-dimethyl-15-oxo-4,7,10,16-tetraoxa-14-azaoctadec-1-yl)-2,3,4,5-tetrahydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 801239-85-0 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-(17,17-dimethyl-15-oxo-4,7,10,16-tetraoxa-14-azaoctadec-1-yl)-2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 801239-86-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-(17,17-dimethyl-15-oxo-4,7,10,16-tetraoxa-14-azaoctadec-1-yl)-2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 801240-04-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-(17,17-dimethyl-15-oxo-4,7,10,16-

tetraoxa-14-azaoctadec-1-yl)-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 801240-05-1 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 8-[2-[6-[[(1,1-dimethylethoxy)carbonyl]methylamino]-2-pyridinyl]ethoxy]-2-(17,17-dimethyl-15-oxo-4,7,10,16-tetraoxa-14-azaoctadec-1-yl)-2,3,4,5-tetrahydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:668007 CAPLUS Full-text
DN 141:332034
TI Multi-Kiloscale Enantioselective Synthesis of a Vitronectin Receptor Antagonist
AU Wallace, Michael D.; McGuire, Michael A.; Yu, Marvin S.; Goldfinger, Lynn; Liu, Li; Dai, Wenning; Shilcrat, Susan
CS Synthetic Chemistry Department, GlaxoSmithKline, King of Prussia, PA, 19406, USA
SO Organic Process Research & Development (2004), 8(5), 738-743
CODEN: OPRDFK; ISSN: 1083-6160
PB American Chemical Society
DT Journal
LA English
OS CASREACT 141:332034
GI



I

AB The development of a novel, cost-effective synthesis of the vitronectin receptor antagonist SB-273005 (I) became necessary as the compound proceeded to Phase 1. A practical synthesis of the compound presented challenges to the process chemist. Chief among the challenges was developing an enantioselective route to the compound Second was either developing a scalable Mitsunobu coupling of the side chain to the main body or finding alternate chemical This paper describes the chemical which allowed the preparation of a hundred kilograms of SB-273005 by a process that is suitable for even larger scale manufacturing

IT 205677-04-9P 773059-56-6P 773059-59-9P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(multi-kiloscale enantioselective synthesis of SB-273005 as a vitronectin receptor antagonist)

RN 205677-04-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 773059-56-6 CAPLUS
CN Butanedioic acid, [(2-formyl-4-hydroxyphenyl)methyl]-, dimethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773059-59-9 CAPLUS
CN Butanedioic acid, [(2-formyl-4-hydroxyphenyl)methyl]-, (2S)-, compd. with N-cyclohexylcyclohexanamine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 773059-58-8
CMF C12 H12 O6

Absolute stereochemistry.



CM 2

CRN 101-83-7
CMF C12 H23 N



IT 205678-31-5P, SB-273005
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(multi-kiloscale enantioselective synthesis of SB-273005 as a vitronectin receptor antagonist)
RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:991468 CAPLUS Full-text
DN 140:27670
TI Preparation of naphththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF)
IN Morand, Eric Francis; Iskander, Magdy Naguib
PA Cortical Pty. Ltd., Australia
SO PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003104178	A1	20031218	WO 2003-AU716	20030606
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2487866	A1	20031218	CA 2003-2487866	20030606
	AU 2003229142	A1	20031222	AU 2003-229142	20030606
	GB 2405146	A	20050223	GB 2004-27241	20030606
	EP 1549598	A1	20050706	EP 2003-724672	20030606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1675154	A	20050928	CN 2003-818936	20030606
	JP 2006511445	T	20060406	JP 2004-511248	20030606
	IN 2004KN01844	A	20060602	IN 2004-KN1844	20040212
	US 2006106102	A1	20060518	US 2005-517240	20051003
PRAI	AU 2002-2833	A	20020607		
	AU 2002-2834	A	20020607		
	WO 2003-AU716	W	20030606		

OS MARPAT 140:27670
GI



I

AB Title compds. I [Y = O, NR9, SOq; R1 = H, alkyl, alkylhalo, alkylalkoxy, etc.;] are prepared For instance, 2,3-dimethoxynaphthalene (preparation given) is acetylated (PhNO2, AcCl, AlCl3) and converted to 6,7-dimethoxy-2- naphthoic acid (water, NaOH, 85°, 60 min). Example compds. are inhibitors of the cytokine or biol. activity of macrophage migration inhibitory factor (MIF). I are useful for the treatment of Lyme disease, connective tissue diseases, etc.

IT 634197-33-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of naphththalene derivs. which inhibit the cytokine or biol. activity of macrophage migration inhibitory factor (MIF))
RN 634197-33-4 CAPLUS
CN Butanedioic acid, [(4-methoxy-2-methylphenyl)methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:847388 CAPLUS Full-text
DN 140:37671
TI Molecular Model of the αIIbβ3 Integrin
AU Feuston, Bradley P.; Culberson, J. Christopher; Hartman, George D.
CS Department of Molecular Systems, Merck Research Laboratories, West Point, PA, 19486, USA
SO Journal of Medicinal Chemistry (2003), 46(25), 5316-5325
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB A mol. model of the αIIbβ3 integrin has been developed utilizing (i) the crystal structure of αvβ3, (ii) homol. model of the αIIb subdomain, and (iii) the docking of αIIbβ3/αvβ3 dual and selective inhibitors into the putative binding sites of αIIbβ3 and αvβ3. Since the binding sites of these integrins are located at the interface between the two heads of the individual subunits, only the αIIbβ3 head region is modeled. The 3D conformations of two loops in αIIb, whose residues have been implicated in non-peptide ligand binding, could not be determined from homol. with αv alone. Mutagenesis data and the modeling of small ligand binding contributed to the rational design of these loop conformations. The final energy minimized loop conformations exhibit permissible ϕ/ψ angles and contribute to a binding site model of αIIbβ3 that is consistent with both the known mutagenesis studies and inhouse structure-activity relationships. The charged residues αIIb:E117 and β3:R214 are found to dominate the ligand-protein binding interaction. The previously identified "exosite" is also identified as a hydrogen bond, hydrophobic or π-π interaction with Y190, similar to the recently proposed binding model of αvβ3.
IT 637032-80-5
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(building of mol. model of αIIbβ3 integrin using a known crystal structure, homol. modeling, and selective inhibitor interaction)
RN 637032-80-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(trifluoromethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:705668 CAPLUS Full-text
DN 140:2336
TI A Humanized Aldolase Antibody for Selective Chemotherapy and Adaptor Immunotherapy
AU Rader, Christoph; Turner, James M.; Heine, Andreas; Shabat, Doron; Sinha, Subhash C.; Wilson, Ian A.; Lerner, Richard A.; Barbas, Carlos F.
CS The Skaggs Institute for Chemical Biology and the Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SO Journal of Molecular Biology (2003), 332(4), 889-899
CODEN: JMOBAK; ISSN: 0022-2836
PB Elsevier
DT Journal
LA English
AB Mouse monoclonal antibody 38C2 is the prototype of a new class of catalytic antibodies that were generated by reactive immunization. Through a reactive lysine, 38C2 catalyzes aldol and retro-aldol reactions using the enamine mechanism of natural aldolases. In addition to its remarkable versatility and efficacy in synthetic organic chemical, 38C2 has been used for the selective activation of prodrugs in vitro and in vivo and thereby emerged as a promising tool for selective chemotherapy. Adding another application with relevance for cancer therapy, designated adaptor immunotherapy, we have recently shown that 38C2 can be chemical programmed to target tumors by formation of a covalent bond of defined stoichiometry with a β-diketone derivative of an integrin αvβ3 targeting RGD peptidomimetic. However, a major limitation for the transition from preclin. to clin. evaluation is the human anti-mouse antibody immune response that mouse 38C2 is likely to elicit in a majority of patients after single administration. Here, we report the humanization of mouse 38C2 based on rational design guided by mol. modeling. In essence, the catalytic center of mouse 38C2, which encompasses a deep hydrophobic pocket with a reactive lysine residue at the bottom, was grafted into a human antibody framework. Humanized 38C2 IgG1 was found to bind to β-diketone haptens with conserved affinities and revealed strong catalytic activity with identical kcat and slightly higher KM values compared to the parental mouse antibody. Furthermore, humanized 38C2 IgG1 revealed efficiency in prodrug activation and chemical programming comparable to the parental mouse antibody.
IT 518315-49-6
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy)
RN 518315-49-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-[19-[[4-(3,5-dioxohexyl)phenyl]amino]-15,19-dioxo-4,7,10-trioxa-14-azanonadec-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:570731 CAPLUS Full-text
DN 139:138717
TI Catalytic antibody targeting compounds
IN Barbas, Carlos F.; Rader, Christoph; Sinha, Subhash C.; Lerner, Richard
PA The Scripps Research Institute, USA
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003059251	A2	20030724	WO 2002-US33991	20021022
	WO 2003059251	A3	20040219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2464472	A1	20030724	CA 2002-2464472	20021022
	AU 2002365182	A1	20030730	AU 2002-365182	20021022
	US 2003175921	A1	20030918	US 2002-278364	20021022
	EP 1443963	A2	20040811	EP 2002-804108	20021022
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1606454	A	20050413	CN 2002-825631	20021022
	JP 2005514430	T	20050519	JP 2003-559416	20021022
	US 2003190676	A1	20031009	US 2003-420373	20030421
PRAI	US 2001-344614P	P	20011022		
	US 2002-412455P	P	20020919		
	US 2002-278364	A1	20021022		
	WO 2002-US33991	W	20021022		

AB The present invention provides antibody targeting compds. in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biol. activity provided by the targeting agent or by a sep. biol. agent. Various uses of the invention compds. are provided.

IT 205677-92-5 518315-47-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(catalytic antibody targeting compds.)

RN 205677-92-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 518315-47-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:373179 CAPLUS Full-text
DN 139:101016
TI Convenient Synthesis of 2-Benzazepines via Radical Cyclization
AU Kamimura, Akio; Taguchi, Yohei; Omata, Yoji; Hagihara, Masahiko
CS Department of Applied Chemistry Faculty of Engineering, Yamaguchi University, Ube, 755-8611, Japan
SO Journal of Organic Chemistry (2003), 68(12), 4996-4998
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 139:101016
GI



I



II

AB Benzazepines I (R = H, MeO; R1 = F3C, Ph, Pr; R2 = Me, MeO2CCH2, EtO2CCH2) were prepared via 7-endo radical cyclization of N-o-bromobenzylitaconamides or N-o-bromobenzylmethacrylamides II, which were prepared in two steps from com. available benzaldehydes, amines, and α,β-unsatd. acids.

IT 558484-04-1P 558484-07-4P 558484-10-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of benzazepines via reductive amination of bromobenzaldehydes, propenoylation of benzylamines, and radical cyclization of (bromobenzyl)propenamides)

RN 558484-04-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-(2,2,2-trifluoroethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 558484-07-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 558484-10-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-butyl-2,3,4,5-tetrahydro-8-methoxy-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:368166 CAPLUS Full-text
DN 138:400106
TI Chemically programmed monoclonal antibodies for cancer therapy: Adaptor immunotherapy based on a covalent antibody catalyst
AU Rader, Christoph; Sinha, Subhash C.; Popkov, Mikhail; Lerner, Richard A.; Barbas, Carlos F., III
CS Department of Molecular Biology and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2003), 100(9), 5396-5400
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
AB Proposing that a blend of the chemical diversity of small synthetic mols. with the immunol. characteristics of the antibody mol. will lead to therapeutic agents with superior properties, the authors here present a device that equips small synthetic mols. with both effector function and long serum half-life of a generic antibody mol. As a prototype, the authors developed a targeting device that is based on the formation of a covalent bond of defined stoichiometry between a 1,3-diketone derivative of an integrin αvβ3 and αvβ5 targeting Arg-Gly-Asp peptidomimetic and the reactive lysine of aldolase antibody 38C2. The resulting complex was shown to (i) spontaneously assemble in vitro and in vivo, (ii) selectively retarget antibody 38C2 to the surface of cells expressing integrins αvβ3 and αvβ5, (iii) dramatically increase the circulatory half-life of the Arg-Gly-Asp peptidomimetic, and (iv) effectively reduce tumor growth in animal models of human Kaposi's sarcoma and colon cancer. This immunotherapeutic has the potential to target a variety of human cancers, acting on both the vasculature that supports tumor growth as well as the tumor cells themselves. Further, by use of a generic antibody mol. that forms a covalent bond with a 1,3-diketone functionality, essentially any compound can be turned into an immunotherapeutic agent thereby not only increasing the diversity space that can be accessed but also multiplying the therapeutic effect.
IT 518315-49-6, SCS 873
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SCS 873; adaptor immunotherapy based on a covalent antibody catalyst)
RN 518315-49-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-[19-[[4-(3,5-dioxohexyl)phenyl]amino]-15,19-dioxo-4,7,10-trioxa-14-azanonadec-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A





RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:334841 CAPLUS Full-text
DN 138:358451
TI Integrin targeting compounds
IN Barbas, Carlos F.; Rader, Christoph; Sinha, Subhash C.
PA The Scripps Research Institute, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003034995	A2	20030501	WO 2002-US33866	20021022
	WO 2003034995	A3	20030912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2464271	A1	20030501	CA 2002-2464271	20021022
	AU 2002337954	A1	20030506	AU 2002-337954	20021022
	US 2003129188	A1	20030710	US 2002-278539	20021022
	EP 1446418	A2	20040818	EP 2002-773859	20021022
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1606566	A	20050413	CN 2002-825588	20021022
	JP 2005532252	T	20051027	JP 2003-537564	20021022
PRAI	US 2001-343799P	P	20011022		
	US 2002-412519P	P	20020919		
	WO 2002-US33866	W	20021022		

AB The present invention is directed to integrin targeting compds. comprising an integrin targeting component linked to a functional component such as a therapeutic agent or antibody. Structures of various integrin targeting compds., e.g. a RGD peptidomimetic, are provided. Also, methods of delivering a functional component to integrin associated with cells or tissue of an individual using the integrin targeting compds., as well as methods of treating or preventing a disease or condition in an individual wherein the disease or condition involves an integrin using the integrin targeting compds. are described. For example, a diketone version of a RGD peptidomimetic specific for human integrin (a binding affinity for αVβ3 = 0.9 nM and for αVβ5 = 0.6 nM), designated SCS-873, was prepared and used for synthesis of the paclitaxel derivative with better soluble paclitaxel-SCS-873.

IT 518315-53-2P, Etoposide-SCS 873
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of integrin targeting compds. containing therapeutic agents or antibody)

RN 518315-53-2 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-[26-[4-[(5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,5a,6,8,8a,9-hexahydro-6-oxofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl]-2,6-dimethoxyphenoxy]-22,25-dimethyl-15,17,21,26-tetraoxo-4,7,10,20-tetraoxa-14,22,25-triazahexacos-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



PAGE 2-C



IT 205677-92-5 518315-47-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of integrin targeting compds. containing therapeutic agents or antibody)

RN 205677-92-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 518315-47-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 518315-49-6P, SCS 873·518329-32-3P, SCS 1655
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of integrin targeting compds. containing therapeutic agents or antibody)

RN 518315-49-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-[19-[[4-(3,5-dioxohexyl)phenyl]amino]-15,19-dioxo-4,7,10-trioxa-14-azanonadec-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 518329-32-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,2'-[21-[5-[[4-(3,5-dioxohexyl)phenyl]amino]-1,5-dioxopentyl]-15,27-dioxo-4,7,10,32,35,38-hexaoxa-14,21,28-triazahentetracontane-1,41-diyl]bis[2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



IT 518315-51-0P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of integrin targeting compds. containing therapeutic agents or antibody)

RN 518315-51-0 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-[22-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-15,19,22-trioxo-4,7,10,20-tetraoxa-14-azadocos-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 518315-49-6DP, SCS 873, conjugates with aldolase monoclonal antibody 518315-50-9P, Paclitaxel-SCS 873 518315-52-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of integrin targeting compds. containing therapeutic agents or antibody)

RN 518315-49-6 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-[19-[[4-(3,5-dioxohexyl)phenyl]amino]-15,19-dioxo-4,7,10-trioxa-14-azanonadec-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 518315-50-9 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-[20-[[[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl]oxy]carbonyl]-15,18,23-trioxo-21,23-diphenyl-4,7,10-trioxa-14,22-diazatricos-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 518315-52-1 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2-[22-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl)-α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-15,19,22-trioxo-4,7,10,20-tetraoxa-14-azadocos-1-yl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:319691 CAPLUS Full-text
DN 138:326535
TI Methods for preventing and treating bone loss in postmenopausal or ovariectomized women with steroid compounds
IN Di Salle, Enrico; Massimini, Giorgio; Lowery, Colin; Goss, Paul Edward
PA Pharmacia Italia S.p.A., Italy; Pharmacia & Upjohn Company
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032961	A2	20030424	WO 2002-EP11123	20020930
	WO 2003032961	A3	20030904		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2463142	A1	20030424	CA 2002-2463142	20020930
	AU 2002333895	A1	20030428	AU 2002-333895	20020930
	EP 1435967	A2	20040714	EP 2002-801313	20020930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013162	A	20040914	BR 2002-13162	20020930
	JP 2005508958	T	20050407	JP 2003-535765	20020930
	CN 1713915	A	20051228	CN 2002-820116	20020930
	NZ 532064	A	20060428	NZ 2002-532064	20020930
	ZA 2004002734	A	20050113	ZA 2004-2734	20040407
PRAI	US 2001-328209P	P	20011010		
	WO 2002-EP11123	W	20020930		

AB A method of preventing and treating abnormal metabolic bone disorders in a postmenopausal or oophorectomized woman is disclosed, which comprises administering an effective amount of exemestane or 17-hydro-exemestane, alone or in combination with addnl. therapeutic agents. Further methods for treating bone disorders are claimed, comprising the administration of exemestane or 17-hydro-exemestane simultaneously, sep. or sequentially with an addnl. therapeutic agent selected from the group consisting of a selective estrogen receptor modulator, an αvβ3 inhibitor or antagonist, a vitamin D or vitamin D derivative, sodium fluoride, a COX-2 inhibitor and a biophosphonate compound, or a mixture thereof.
IT 205678-31-5, SB-273005
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compds. for preventing and treating bone loss in postmenopausal or ovariectomized women with steroid compds. administered in conjunction with an αvβ3 inhibitor or antagonist)
RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:868905 CAPLUS Full-text
DN 137:370076
TI Preparation of naphthyridinylethoxybenzazepinones and related compounds as αv integrin receptor antagonists
IN Meissner, Robert S.; Coleman, Paul J.; Duggan, Mark E.; Hartman, George D.; Hutchinson, John H.; Wang, Jiabing
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002090325	A2	20021114	WO 2002-US13457	20020429
	WO 2002090325	A3	20030227		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2445679	A1	20021114	CA 2002-2445679	20020429
	AU 2002256387	A1	20021118	AU 2002-256387	20020429
	EP 1387688	A2	20040211	EP 2002-725848	20020429
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004528373	T	20040916	JP 2002-587405	20020429
	US 2004142919	A1	20040722	US 2003-475697	20031021
	US 7109191	B2	20060919		
PRAI	US 2001-288578P	P	20010503		
	WO 2002-US13457	W	20020429		

OS MARPAT 137:370076
GI



I

AB Title compds. [I; X = (substituted) tetrahydronaphthyridinyl, pyridoazepinyl, aminopyridinyl; R1 = H, alkyl], were prepared as antagonists of the integrin receptors αvβ3 and αvβ5 and are therefore useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth (no data). Thus, 5,6,7,8-tetrahydro-1,8-naphthyridin-2-ylethanol, Me (4S)-3-oxo-8-hydroxy-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2- benzazepin-4-

acetate, Ph3P, and di-Et azodicarboxylate were stirred in THF at 0° to room temperature to give the ether coupling product, which was saponified with aqueous NaOH in dioxane to give (4S)-3-oxo-8-[2-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5- tetrahydro-1H-benzazepin-4-acetic acid.

IT 475204-25-2P 475204-26-3P 475204-27-4P
475204-28-5P 475204-29-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of naphthyridinylethoxybenzazepinones and related compds. as αv integrin receptor antagonists)

RN 475204-25-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475204-26-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[2-(1,5,6,7-tetrahydro-7-methyl-1,8-naphthyridin-2-yl)ethoxy]-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475204-27-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[2-(5,6,7,8-tetrahydro-1H-pyrido[2,3-b]azepin-2-yl)ethoxy]-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475204-28-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[2-(2',3'-dihydrospiro[cyclopropane-1,4'(1'H)-[1,8]naphthyridin]-7'-yl)ethoxy]-2,3,4,5-tetrahydro-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475204-29-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[2-[3-cyclopropyl-6-(methylamino)-2-pyridinyl]ethoxy]-2,3,4,5-tetrahydro-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 475204-30-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of naphthyridinylethoxybenzazepinones and related
compds. as αv integrin receptor antagonists)
RN 475204-30-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 205677-04-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of naphthyridinylethoxybenzazepinones and related compds. as αv integrin receptor antagonists)
RN 205677-04-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L11 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:844382 CAPLUS Full-text
DN 138:66643
TI Binding Model for Nonpeptide Antagonists of αvβ3 Integrin
AU Feuston, Bradley P.; Culberson, J. Chris; Duggan, Mark E.; Hartman, George D.; Leu, Chih-Tai; Rodan, Sevgi B.
CS Departments of Molecular Systems Medicinal Chemistry and Bone Biology Osteoporosis Research, Merck Research Laboratories, West Point, PA, 19486, USA
SO Journal of Medicinal Chemistry (2002), 45(26), 5640-5648
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB A binding model for nonpeptide antagonists of integrin αvβ3 has been developed through docking analyses utilizing the MMFFs force field and the recently published crystal structure, 1JV2. Results of this docking study have led to the identification of a novel binding model for selective antagonists of αvβ3 over αIIbβ3 integrins. Four different chemical classes are shown to bind in a similar fashion providing a measure of confidence in the proposed model. All αvβ3 and αIIbβ3 antagonists have a basic nitrogen separated some distance from a carboxylic acid to mimic RGD. For the αvβ3 antagonists under present consideration, these charged ends are separated by twelve bonds. The basic nitrogen of the active αvβ3 ligands are shown to interact with D150 of αv and the ligands' carboxylic acid interact with R214 of β3 while adopting an extended conformation with minimal protein induced internal strain. In addition, an energetically favorable interaction is found with all of the active αvβ3 mols. with Y178 of αv when docked to the crystallog. determined structure. This novel interaction may be characterized as π-π stacking for the most active of the αvβ3 selective antagonists. The proposed model is consistent with observed activity as well as mutagenicity and photoaffinity crosslinking studies of the αvβ3 integrin.
IT 205678-31-5
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(binding model for nonpeptide antagonists of αvβ3 integrin)
RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:813921 CAPLUS Full-text
DN 137:304827
TI Method of inhibiting adhesion formation
IN Willette, Robert N.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083125	A1	20021024	WO 2002-US11285	20020410
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2443734	A1	20021024	CA 2002-2443734	20020410
	AU 2002305164	A1	20021028	AU 2002-305164	20020410
	EP 1385504	A1	20040204	EP 2002-733968	20020410
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 200303725	A2	20040301	HU 2003-3725	20020410
	BR 2002008789	A	20040309	BR 2002-8789	20020410
	CN 1509170	A	20040630	CN 2002-809787	20020410
	JP 2004525959	T	20040826	JP 2002-580929	20020410
	NZ 528577	A	20050128	NZ 2002-528577	20020410
	ZA 2003007621	A	20040421	ZA 2003-7621	20030930
	BG 108217	A	20041230	BG 2003-108217	20031001
	NO 2003004513	A	20031204	NO 2003-4513	20031008
	US 2004142918	A1	20040722	US 2003-474540	20031009
	MX 2003PA09344	A	20040212	MX 2003-PA9344	20031010
	IN 2003DN01702	A	20051014	IN 2003-DN1702	20031017
	US 2007149505	A1	20070628	US 2007-676359	20070219
PRAI	US 2001-282693P	P	20010410		
	WO 2002-US11285	W	20020410		
	US 2003-474540	A1	20031009		

AB The invention discloses the use of a vitronectin receptor antagonist to inhibit adhesion formation.
IT 205678-26-8 205678-31-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of inhibiting adhesion formation)
RN 205678-26-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205678-31-5 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:520405 CAPLUS Full-text
DN 138:117608
TI Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist
AU Hoffman, Sandra J.; Vasko-Moser, Janice; Miller, William H.; Lark, Michael W.; Gowen, Maxine; Stroup, George
CS Departments of Musculoskeletal Diseases, GlaxoSmithKline, King of Prussia, PA, USA
SO Journal of Pharmacology and Experimental Therapeutics (2002), 302(1), 205-211
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB An excess of thyroid hormone results in increased bone turnover and loss of bone mass in humans. Exogenous administration of thyroid hormone to rats has served as a model of human hyperthyroidism in which antiresorptive therapies have been tested. We have further refined this model of thyroxine (T4)-induced turnover in the rat. Daily administration of T4 to aged rats for as short as 1 wk resulted in elevated bone resorption determined by significantly higher urinary deoxypyridinoline (Dpd) compared with vehicle controls or animals receiving T4 plus estradiol. Three weeks of daily administration of T4 led to significantly lower bone mineral d. compared with untreated controls or animals receiving T4 plus estradiol. In a follow-up study, a depot formulation of T4 caused an increase in Dpd identical to that achieved with a bolus dose. SB-273005 [(4S)-2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2- (2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetic acid] a potent antagonist of the integrins αvβ3 and αvβ5, has been shown previously to inhibit bone resorption in cultures of human osteoclasts and to protect bone in ovariectomized rats. The effect of SB-273005 by oral administration was evaluated in this thyroxine-induced turnover model. Dose-dependent inhibition of resorption was seen with SB-273005 after 7 days of dosing using Dpd as a measure of bone resorption. In summary, it has been demonstrated that the antiresorptive activity of a vitronectin receptor antagonist can be measured after only 7 days of treatment in this refined rat model of thyroxine-induced bone turnover. These data suggest that SB-273005 may be useful for the treatment of metabolic bone diseases, including those resulting from hyperthyroidism.
IT 205678-31-5, SB 273005
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally active vitronectin receptor antagonist inhibition of thyroxine-induced bone resorption)
RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:128172 CAPLUS Full-text
DN 135:132013
TI Disease-modifying activity of SB 273005, an orally active, nonpeptide αvβ3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis
AU Badger, Alison M.; Blake, Simon; Kapadia, Rasesh; Sarkar, Susanta; Levin, Joshua; Swift, Barbara A.; Hoffman, Sandy J.; Stroup, George B.; Miller, William H.; Gowen, Maxine; Lark, Michael W.
CS SmithKline Beecham Pharmaceuticals, King of Prussia, PA, 19406, USA
SO Arthritis & Rheumatism (2001), 44(1), 128-137
CODEN: ARHEAW; ISSN: 0004-3591
PB Wiley-Liss, Inc.
DT Journal
LA English
AB Objective. To evaluate the effects of SB 273005, a potent, orally active nonpeptide antagonist of the integrin αvβ3 vitronectin receptor, on joint integrity in rats with adjuvant-induced arthritis (AIA). Methods. Male Lewis rats with AIA were orally dosed either prophylactically (days 0-20) or therapeutically (days 10-20) with SB 273005. Efficacy was determined by measurement of paw inflammation, assessment of bone mineral d. using dual-energy x-ray absorptiometry (DEXA), magnetic resonance imaging (MRI), and histol. evaluation. Results. SB 273005 is a potent antagonist of the closely related integrins, αvβ3 (Ki = 1.2 nM) and αvβ5 (Ki = 0.3 nM). When SB 273005 was administered prophylactically to AIA rats twice per day, it inhibited paw edema at doses of 10, 30, and 60 mg/kg, by 40%, 50%, and 52%, resp. Therapeutic administration twice daily was also effective, and a reduction in paw edema was observed at 30 mg/kg and 60 mg/kg of the antagonist (by 36% and 48%, resp.). SB 273005 was also effective when administered once per day, both prophylactically and therapeutically. Significant improvement in joint integrity in treated rats was shown using DEXA and MRI analyses. These findings were confirmed histol., and significant protection of bone, cartilage, and soft tissue was observed within the joint. Conclusion. Symptoms of AIA in rats were significantly reduced by either prophylactic or therapeutic treatment with the αvβ3 antagonist, SB 273005. Measurements of paw inflammation and of bone, cartilage, and soft tissue structure indicated that this compound exerts a protective effect on joint integrity and thus appears to have disease-modifying properties.
IT 205678-31-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SB 273005 disease-modifying activity in rats with adjuvant-induced arthritis)
RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:115149 CAPLUS Full-text
DN 134:157565
TI Vitronectin receptor antagonists useful for the treatment of strokes
IN Barone, Frank C.; Yue, Tian-Li
PA SmithKline Beecham Corporation, USA
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010867	A1	20010215	WO 2000-US21433	20000804
	W: AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1208101	A1	20020529	EP 2000-952558	20000804
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003506452	T	20030218	JP 2001-515676	20000804
PRAI	US 1999-147567P	P	19990806		
	WO 2000-US21433	W	20000804		

OS MARPAT 134:157565
AB This invention relates to the use of a vitronectin receptor antagonist to treat stroke. The antagonist is a benzazepine ether.
IT 205678-26-8 205678-26-8D, pharmaceutically acceptable salts 205678-31-5 205678-31-5D, pharmaceutically acceptable salts
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitronectin receptor antagonists useful for treatment of strokes)
RN 205678-26-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205678-26-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:93796 CAPLUS Full-text
DN 135:102507
TI Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat
AU Lark, Michael W.; Stroup, George B.; Dodds, Robert A.; Kapadia, Rasesh; Hoffman, Sandra J.; Hwang, Shing Mei; James, Ian E.; Lechowska, Beata; Liang, Xiaoguang; Rieman, David J.; Salyers, Kevin L.; Ward, Keith; Smith, Brian R.; Miller, William H.; Huffman, William F.; Gowen, Maxine
CS Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA
SO Journal of Bone and Mineral Research (2001), 16(2), 319-327
CODEN: JBMREJ; ISSN: 0884-0431
PB American Society for Bone and Mineral Research
DT Journal
LA English
AB An orally active, nonpeptide Arg-Gly-Asp (RGD) mimetic αvβ3 antagonist, (S)-3-Oxo-8-[2-[6-(methylamino)-pyridin-2-yl]-1-ethoxy]-2- (2,2, 2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid (compound 1), has been generated, which prevented net bone loss and inhibited cancellous bone turnover in vivo. The compound binds αvβ3 and the closely related integrin αvβ5 with low nanomolar affinity but binds only weakly to the related integrins αIIbβ3, and α5β1. Compound 1 inhibited αvβ3-mediated cell adhesion with an IC50 = 3 nM. More importantly, the compound inhibited human osteoclast-mediated bone resorption in vitro with an IC50 = 11 nM. In vivo, compound 1 inhibited bone resorption in a dose-dependent fashion, in the acute thyroparathyroidectomized (TPTX) rat model of bone resorption with a circulating EC50 .apprx.20 μM. When dosed orally at 30 mg/kg twice a day (b.i.d.) in the chronic ovariectomy (OVX)-induced rat model of osteopenia, compound 1 also prevented bone loss. At doses ranging from 3 to 30 mg/kg b.i.d., compound 1 partially prevented the OVX-induced increase in urinary deoxypyridinoline. In addition, the compound prevented the OVX-induced reduction in cancellous bone volume (BV), trabecular number (Tb.N), and trabecular thickness (Tb.Th), as assessed by quant. microcomputerized tomog. (μCT) and static histomorphometry. Furthermore, both the 10-mg/kg and 30-mg/kg doses of compound prevented the OVX-induced increase in bone turnover, as measured by percent osteoid perimeter (%O.Pm). Together, these data indicate that the αvβ3 antagonist compound 1 inhibits OVX-induced bone loss. Mechanistically, compound 1 prevents bone loss in vivo by inhibiting osteoclast-mediated bone resorption, ultimately preventing cancellous bone turnover.
IT 205678-31-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(osteoclast vitronectin receptor antagonism with orally active nonpeptide inhibitor prevents cancellous bone loss in ovariectomized rats)
RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:807528 CAPLUS Full-text
DN 132:146616
TI Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic
AU Miller, William H.; Alberts, Doreen P.; Bhatnagar, Pradip K.; Bondinell, William E.; Callahan, James F.; Calvo, Raul R.; Cousins, Russell D.; Erhard, Karl F.; Heerding, Dirk A.; Keenan, Richard M.; Kwon, Chet; Manley, Peter J.; Newlander, Kenneth A.; Ross, Stephen T.; Samanen, James M.; Uzinskas, Irene N.; Venslavsky, Joseph W.; Yuan, Catherine C.-K.; Haltiwanger, R. Curtis; Gowen, Maxine; Hwang, Shing-Mei; James, Ian E.; Lark, Michael W.; Rieman, David J.; Stroup, George B.; Azzarano, Leonard M.; Salyers, Kevin L.; Smith, Brian R.; Ward, Keith W.; Johanson, Kyung O.; Huffman, William F.
CS Research & Development Division, SmithKline Beecham Pharmaceuticals, Collegeville, PA, 19426-0989, USA
SO Journal of Medicinal Chemistry (2000), 43(1), 22-26
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB A new series of small mol. RGD mimetics that are highly potent, orally active αvβ3 antagonists is described. Selected members of this series are potent inhibitors of bone resorption in vitro and in vivo and have activity in an animal model of osteoporosis.
IT 258282-33-6
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine gly-asp mimetic)
RN 258282-33-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-3-oxo-8-[3-(2-pyridinylamino)propoxy]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 205678-16-6P 205678-26-8P 205678-27-9P
205678-31-5P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine gly-asp mimetic)
RN 205678-16-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 205678-26-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205678-27-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 205676-76-2P 205676-77-3P 205676-78-4P
205677-02-7P 205677-04-9P 205677-80-1P

205677-81-2P 205677-86-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine gly-asp mimetic)

RN 205676-76-2 CAPLUS
CN Butanedioic acid, [[2-[[[(1,1-dimethylethoxy)carbonyl](2,2,2-trifluoroethyl)amino]methyl]-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-77-3 CAPLUS
CN Butanedioic acid, [[4-methoxy-2-[[(2,2,2-trifluoroethyl)amino]methyl]phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-78-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-02-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205677-04-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)-. (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205677-80-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-81-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-86-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:231510 CAPLUS Full-text
DN 130:237491
TI Preparation of benzazepineacetic acid derivative as vitronectin receptor antagonist
IN Miller, William H.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915178	A1	19990401	WO 1998-US19987	19980924
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2304000	A1	19990401	CA 1998-2304000	19980924
	AU 9895787	A	19990412	AU 1998-95787	19980924
	EP 1023073	A1	20000802	EP 1998-949471	19980924
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	TR 200000786	T2	20000821	TR 2000-200000786	19980924
	BR 9813214	A	20000829	BR 1998-13214	19980924
	HU 200003931	A2	20011028	HU 2000-3931	19980924
	JP 2002500162	T	20020108	JP 2000-512547	19980924
	NO 2000001515	A	20000323	NO 2000-1515	20000323
	MX 200002895	A	20010827	MX 2000-2895	20000323
	US 2002019387	A1	20020214	US 2001-956682	20010920
	US 2002123487	A1	20020905	US 2002-134923	20020429
PRAI	US 1997-59867P	P	19970924		
	WO 1998-US19987	W	19980924		
	US 2000-509184	A1	20000321		
	US 2001-956682	A1	20010920		

OS MARPAT 130:237491
GI



I

AB The title compound I, a vitronectin receptor antagonist, was prepared
IT 221305-62-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzazepineacetic acid derivative as vitronectin receptor antagonist)
RN 221305-62-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methyl-2-pyridinyl)amino]propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-,

(4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 205676-64-8P 205676-65-9P 205676-79-5P
205676-80-8P 205676-81-9P 205676-82-0P
221313-50-4P 221313-51-5P 221313-52-6P
221313-53-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzazepineacetic acid derivative as vitronectin receptor antagonist)

RN 205676-64-8 CAPLUS
CN Butanedioic acid, [[2-[[bis[(1,1-dimethylethoxy)carbonyl]amino]methyl]-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-65-9 CAPLUS
CN Butanedioic acid, [[2-(aminomethyl)-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-79-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205676-80-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205676-81-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205676-82-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 221313-50-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl](1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221313-51-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl](1-

oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[(2,3,4-trifluorophenyl)methyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221313-52-6 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-[(2,3,4-trifluorophenyl)methyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221313-53-7 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-[(2,3,4-trifluorophenyl)methyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:231502 CAPLUS Full-text
DN 130:237490
TI Preparation of benzazepineacetic acid derivative as vitronectin receptor antagonist
IN Miller, William H.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915170	A1	19990401	WO 1998-US19949	19980924
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2303846	A1	19990401	CA 1998-2303846	19980924
	AU 9895774	A	19990412	AU 1998-95774	19980924
	EP 1017387	A1	20000712	EP 1998-949454	19980924
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	BR 9813208	A	20000822	BR 1998-13208	19980924
	TR 200000792	T2	20000921	TR 2000-200000792	19980924
	HU 200003949	A2	20011028	HU 2000-3949	19980924
	JP 2002528380	T	20020903	JP 2000-512539	19980924
	NO 2000001514	A	20000323	NO 2000-1514	20000323
	MX 200002896	A	20010827	MX 2000-2896	20000323
	US 2001014737	A1	20010816	US 2001-800057	20010305
	US 2002040136	A1	20020404	US 2001-996141	20011128
	US 2002128257	A1	20020912	US 2002-141313	20020508
	US 2003087894	A1	20030508	US 2002-277289	20021022
	US 2003216377	A1	20031120	US 2003-430169	20030505
PRAI	US 1997-59832P	P	19970924		
	WO 1998-US19949	W	19980924		
	US 2000-509142	B1	20000322		
	US 2001-800057	A1	20010305		
	US 2001-996141	B1	20011128		
	US 2002-141313	A1	20020508		
	US 2002-277289	B1	20021022		

OS MARPAT 130:237490
GI



I

AB The title compound I, a vitronectin receptor antagonist, was prepared in several steps.
IT 221305-62-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzazepineacetic acid derivative as vitronectin receptor antagonist)

RN 221305-62-0 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methyl-2-pyridinyl)amino]propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 205676-64-8P 205676-65-9P 205676-79-5P
205676-80-8P 205676-81-9P 205676-82-0P
205676-91-1P 205676-92-2P 205677-00-5P
221305-59-5P 221305-60-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzazepineacetic acid derivative as vitronectin receptor antagonist)

RN 205676-64-8 CAPLUS

CN Butanedioic acid, [[2-[[bis[(1,1-dimethylethoxy)carbonyl]amino]methyl]-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-65-9 CAPLUS

CN Butanedioic acid, [[2-(aminomethyl)-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-79-5 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205676-80-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205676-81-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205676-82-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205676-91-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[[4-(trifluoromethyl)phenyl]methoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205676-92-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (4S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry. Rotation (-).



RN 205677-00-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221305-59-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methyl-1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221305-60-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methyl-2-pyridinyl)amino]propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:239115 CAPLUS Full-text
DN 128:294793
TI Preparation of benzodiazepines and dibenzo[a,d]cycloheptanes for stimulating bone formation
IN Drake, Fred H.
PA Smithkline Beecham Corporation, USA; Drake, Fred H.
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9815278	A1	19980416	WO 1997-US18178	19971007
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 946180	A1	19991006	EP 1997-945563	19971007
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2001501951	T	20010213	JP 1998-517727	19971007
	US 2002032187	A1	20020314	US 2001-956659	20010920
PRAI	US 1996-27764P	P	19961007		
	WO 1997-US18178	W	19971007		
	US 1999-284055	B1	19990407		
	US 2000-639347	A1	20000816		

OS MARPAT 128:294793
GI



AB The title compds. [I or II; X-X1 = NR1CH, N:C, CR1:C, etc.; R1 = H, C1-6 alkyl, Ar-C1-6 alkyl; R2 = (CH2)nCO2R'; R3 = H, C1-6 alkyl, Ar-C0-6 alkyl, etc.; R4 = W-(Q')p(CR'2)qU(CR'2)s; R' = H, C1-6 alkyl, C3-7 cycloalkyl, etc.; Q' = NR5, S, CR5; U = NR6C(O), C(O)NR6, CH2CO, etc.; R5, R6 = H, C1-6 alkyl, etc.; W = (un)substituted pyridyl, piperidinyl, imidazolyl, etc.; n = 1-2; p = 0-1; q = 0-3; s = 0-3], integrin binding compds. which cause the release of osteocalcin from osteoblasts, and are therefore useful for treating osteoporosis, hyperparathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, or bone loss due to immobilization or sex hormone deficiency, were prepared and formulated. Thus, treatment of Me (±)-7-carboxy-4- methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate with SOCl2 followed by reaction of the resulting intermediate with 2-(aminomethyl)benzimidazole.2HCl in the presence of pyridine and Et3N in CH2Cl2, and hydrolysis of the acetate with 1.0 LiOH in THF/H2O afforded the title compound I [X = NH; X1 = CH; R2 = CH2COOH; R3 = Me; R4 = {[(2-benzimdazolyl)methyl]amino}carbonyl]. Prepared compds. I or II showed EC50 of < 1 μM in the ROS 17/2.8 osteocalcin assay.

IT 205677-90-3P 205677-92-5P 205678-30-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzodiazepines and dibenzo[a,d]cycloheptanes for stimulating bone formation)

RN 205677-90-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-92-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 205678-30-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-2-(2-phenylethyl)-8-[3-(2-pyridinylamino)propoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 205676-61-5P 205676-64-8P 205676-65-9P
205676-66-0P 205676-68-2P 205676-69-3P
205676-70-6P 205676-71-7P 205677-16-3P
205677-17-4P 205677-18-5P 205677-19-6P
205677-43-6P 205677-44-7P 205677-45-8P
205677-87-8P 205677-88-9P 205677-89-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzodiazepines and dibenzo[a,d]cycloheptanes for stimulating bone formation)

RN 205676-61-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205676-64-8 CAPLUS
CN Butanedioic acid, [[2-[[bis[(1,1-dimethylethoxy)carbonyl]amino]methyl]-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-65-9 CAPLUS
CN Butanedioic acid, [[2-(aminomethyl)-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-66-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205676-68-2 CAPLUS
CN Butanedioic acid, [[2-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-

4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-69-3 CAPLUS
CN Butanedioic acid, 2-[[4-methoxy-2-[(methylamino)methyl]phenyl]methyl]-, 1,4-dimethyl ester (CA INDEX NAME)



RN 205676-70-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-2-methyl-3-oxo-, methyl ester (CA INDEX NAME)



RN 205676-71-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-, methyl ester (CA INDEX NAME)



RN 205677-16-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-(2-phenylethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-17-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2-phenylethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-18-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-19-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 205677-43-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-8-[3-[[[(4-nitrophenyl)methoxy]carbonyl]amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-44-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-(3-aminopropoxy)-2,3,4,5-tetrahydro-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-45-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-87-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-(2-phenylethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-88-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-2-(2-phenylethyl)-8-[3-(2-pyridinylamino)propoxy]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-89-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2-phenylethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:219717 CAPLUS Full-text
DN 128:282853
TI Oxotetrahydrobenzazepine compounds for vitronectin receptor antagonists
IN Callahan, James Francis; Cousins, Russell Donovan; Keenan, Richard M.; Kwon, Chet; Miller, William Henry; Uzinkas, Irene Nijole
PA Smithkline Beecham Corp., USA
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9814192	A1	19980409	WO 1997-US18001	19971001
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AZ, BY, KZ, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	IN 1997DE02758	A	20050311	IN 1997-DE2758	19970926
	ZA 9708798	A	19980402	ZA 1997-8798	19971001
	CA 2267224	A1	19980409	CA 1997-2267224	19971001
	CA 2267224	C	20070313		
	AU 9747462	A	19980424	AU 1997-47462	19971001
	AU 733417	B2	20010517		
	BR 9712248	A	19990824	BR 1997-12248	19971001
	EP 957917	A1	19991124	EP 1997-909979	19971001
	EP 957917	B1	20051207		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	CN 1238689	A	19991215	CN 1997-180168	19971001
	CN 1114403	B	20030716		
	NZ 334953	A	20000128	NZ 1997-334953	19971001
	HU 9903769	A2	20000328	HU 1999-3769	19971001
	JP 2001501936	T	20010213	JP 1998-516942	19971001
	IL 129243	A	20040725	IL 1997-129243	19971001
	RO 119881	B1	20050530	RO 1999-353	19971001
	AP 1463	A	20050930	AP 1999-1493	19971001
	W: BW, GH, GM, KE, LS, MZ, SL, SZ, UG, ZW, ZM				
	AT 312089	T	20051215	AT 1997-909979	19971001
	PL 190859	B1	20060228	PL 1997-332674	19971001
	SK 285029	B6	20060406	SK 1999-425	19971001
	ES 2252775	T3	20060516	ES 1997-909979	19971001
	TW 487702	B	20020521	TW 1997-86114545	19980210
	NO 9901590	A	19990531	NO 1999-1590	19990331
	NO 320194	B1	20051114		
	BG 64581	B1	20050831	BG 1999-103299	19990331
	KR 2000048816	A	20000725	KR 1999-702811	19990401
	HK 1023730	A1	20060811	HK 2000-103033	20000522
	US 2003125317	A1	20030703	US 2002-320084	20021216
	US 2004082559	A1	20040429	US 2003-691241	20031022
	US 6825188	B2	20041130		
PRAI	US 1996-27320P	P	19961002		
	US 1997-43776P	P	19970411		
	WO 1997-US18001	W	19971001		
	US 1999-269824	B1	19990401		
	US 2000-668962	B1	20000925		
	US 2001-973973	A1	20011009		

US 2002-320084 A1 20021216
OS CASREACT 128:282853; MARPAT 128:282853
GI


I


II


III


IV

AB The title compds. I [R1 = R7, (un)substituted A-C0-4 alkyl, A-C2-4 alkenyl, A-C2-4 alkynyl, etc.; A = H, C3-6 cycloalkyl, Het or Ar; R7 = COR8, COCR'2R9, etc.; R8 = OR', NR'R'', NR'SO2R', etc.; R9 = OR', CN, COR', etc.; R2 = II, III, IV, etc.; R' = H, C1-6 alkyl, Ar-C0-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl; R'' = R', COR', CO2R'; R''' = H, C1-6 alkyl, Ar-C0-6 alkyl, etc.; W = (CHRg)aU(CHRg)b; U = CO, O, OCO, etc.; G = NRe, S, O; Rg = H, C1-6 alkyl, Het-C0-6 alkyl, etc.; Re = H, C1-6 alkyl, Ar-C0-6 alkyl, etc.; a, b = 0, 1, 2] or a pharmaceutically acceptable salt thereof, are prepared The compds. are useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation. Thus, (±)-8-[3-(2-pyridylamino)-1- propyloxy]-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepin-4-acetic acid and its parenteral and oral dosage unit compns. were prepared

IT 205677-90-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(oxotetrahydrobenzazepine compds. for vitronectin receptor antagonists)
RN 205677-90-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 205677-92-5P 205677-93-6P 205677-94-7P
205677-95-8P 205677-96-9P 205677-97-0P
205677-98-1P 205677-99-2P 205678-00-8P
205678-01-9P 205678-02-0P 205678-03-1P
205678-04-2P 205678-05-3P 205678-06-4P
205678-07-5P 205678-08-6P 205678-09-7P
205678-10-0P 205678-11-1P 205678-12-2P
205678-13-3P 205678-14-4P 205678-15-5P
205678-16-6P 205678-17-7P 205678-18-8P
205678-19-9P 205678-20-2P 205678-21-3P

205678-22-4P 205678-24-6P 205678-25-7P
205678-26-8P 205678-27-9P 205678-28-0P
205678-29-1P 205678-30-4P 205678-31-5P
205678-32-6P 205678-33-7P 205678-34-8P
205678-35-9P 205678-36-0P 205678-37-1P
205678-38-2P 205678-39-3P 205678-40-6P
205678-41-7P 205678-42-8P 205678-43-9P
205678-44-0P 205678-45-1P 205678-46-2P
205678-47-3P 205678-48-4P 205678-49-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oxotetrahydrobenzazepine compds. for vitronectin receptor antagonists)

RN 205677-92-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 205677-93-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4-amino-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo- (9CI) (CA INDEX NAME)



RN 205677-94-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methoxy-2-pyridinyl)amino]propoxy]-3-oxo- (9CI) (CA INDEX NAME)



RN 205677-95-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 205677-96-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-(1H-imidazol-2-ylamino)propoxy]-3-oxo- (9CI) (CA INDEX NAME)



RN 205677-97-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 205677-98-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(6-amino-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo- (9CI) (CA INDEX NAME)



RN 205677-99-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[2-(1H-benzimidazol-2-yl)ethoxy]-2,3,4,5-tetrahydro-3-oxo- (9CI) (CA INDEX NAME)



RN 205678-00-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethoxy]-3-oxo- (9CI) (CA INDEX NAME)



RN 205678-01-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo- (9CI) (CA INDEX NAME)



RN 205678-02-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4-amino-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 205678-03-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyrimidinylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 205678-04-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4-amino-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205678-05-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4-amino-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205678-06-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo- (9CI) (CA INDEX NAME)



RN 205678-07-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl](1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo- (9CI) (CA INDEX NAME)



RN 205678-08-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 205678-09-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 205678-10-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-8-[3-(methyl-2-pyridinylamino)propoxy]-3-oxo- (9CI) (CA INDEX NAME)



RN 205678-11-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-2-(phenylmethyl)-

8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 205678-12-2 CAPLUS
CN 2H-2-Benzazepine-2,4-diacetic acid, 1,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 205678-13-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-[(4-aminophenyl)methyl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 205678-14-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-(benzoyl-2-pyridinylamino)propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 205678-15-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 205678-16-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 205678-17-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[2-(2-amino-4-thiazolyl)ethoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 205678-18-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4,6-dimethyl-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 205678-19-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-3-oxo-8-[3-[(4,5,6,7-tetrahydro-1H-1,3-diazepin-2-yl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 205678-20-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(3,3-dimethyl-1-oxobutyl)-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 205678-21-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[[(2-methylpropoxy)carbonyl]-2-pyridinylamino]propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 205678-22-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205678-24-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methyl-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 205678-25-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-(methyl-2-pyridinylamino)propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 205678-26-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205678-27-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205678-28-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methyl-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205678-29-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205678-30-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-2-(2-phenylethyl)-8-[3-(2-pyridinylamino)propoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205678-31-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, (4S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 205678-32-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205678-33-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 205678-34-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-3-oxo-8-[3-(2-pyridinylamino)propoxy]-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 205677-95-8
CMF C21 H25 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-35-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4-amino-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-02-0
CMF C21 H26 N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-36-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4-amino-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 205678-37-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 205678-38-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-09-7
CMF C28 H28 F3 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-39-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-8-[3-(methyl-2-pyridinylamino)propoxy]-3-oxo-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-10-0
CMF C22 H27 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-40-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-2-(phenylmethyl)-8-[3-(2-pyridinylamino)propoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-11-1
CMF C27 H29 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-41-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-[(4-aminophenyl)methyl]-2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-13-3
CMF C27 H30 N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-42-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-(benzoyl-2-pyridinylamino)propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (20:17) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-14-4
CMF C35 H32 F3 N3 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-43-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-15-5
CMF C19 H26 N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-44-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[2-(2-amino-4-thiazolyl)ethoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo-, trifluoroacetate (10:13) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-17-7
CMF C18 H21 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-45-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4,6-dimethyl-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo-, hydrochloride (2:1) (9CI) (CA INDEX NAME)



●1/2 HCl

RN 205678-46-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-3-oxo-8-[3-(2-pyridinylamino)propoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 205678-47-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]-, (S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-22-4
CMF C28 H28 F3 N3 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-48-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-(methyl-2-pyridinylamino)propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-25-7
CMF C29 H30 F3 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205678-49-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]-, (S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205678-29-1
CMF C27 H31 F3 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 205676-61-5P 205676-64-8P 205676-65-9P
205676-66-0P 205676-68-2P 205676-69-3P
205676-70-6P 205676-71-7P 205676-75-1P
205676-76-2P 205676-77-3P 205676-78-4P
205676-79-5P 205676-80-8P 205676-81-9P
205676-82-0P 205676-91-1P 205676-92-2P
205677-00-5P 205677-01-6P 205677-02-7P
205677-03-8P 205677-04-9P 205677-16-3P
205677-17-4P 205677-18-5P 205677-19-6P
205677-20-9P 205677-21-0P 205677-22-1P
205677-23-2P 205677-24-3P 205677-25-4P
205677-26-5P 205677-28-7P 205677-29-8P
205677-30-1P 205677-31-2P 205677-32-3P
205677-33-4P 205677-34-5P 205677-35-6P
205677-36-7P 205677-37-8P 205677-38-9P
205677-39-0P 205677-40-3P 205677-41-4P
205677-42-5P 205677-43-6P 205677-44-7P
205677-45-8P 205677-46-9P 205677-47-0P
205677-48-1P 205677-49-2P 205677-50-5P
205677-51-6P 205677-52-7P 205677-53-8P
205677-54-9P 205677-55-0P 205677-56-1P
205677-57-2P 205677-58-3P 205677-59-4P
205677-60-7P 205677-61-8P 205677-62-9P
205677-63-0P 205677-64-1P 205677-65-2P
205677-66-3P 205677-67-4P 205677-68-5P
205677-69-6P 205677-70-9P 205677-71-0P
205677-72-1P 205677-73-2P 205677-74-3P
205677-75-4P 205677-76-5P 205677-77-6P
205677-78-7P 205677-79-8P 205677-80-1P
205677-81-2P 205677-82-3P 205677-83-4P
205677-84-5P 205677-85-6P 205677-86-7P
205677-87-8P 205677-88-9P 205677-89-0P
205677-91-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(oxotetrahydrobenzazepine compds. for vitronectin receptor antagonists)

RN 205676-61-5 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205676-64-8 CAPLUS

CN Butanedioic acid, [[2-[[bis[(1,1-dimethylethoxy)carbonyl]amino]methyl]-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-65-9 CAPLUS

CN Butanedioic acid, [[2-(aminomethyl)-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-66-0 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205676-68-2 CAPLUS
CN Butanedioic acid, [[2-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-69-3 CAPLUS
CN Butanedioic acid, 2-[[4-methoxy-2-[(methylamino)methyl]phenyl]methyl]-, 1,4-dimethyl ester (CA INDEX NAME)



RN 205676-70-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-2-methyl-3-oxo-, methyl ester (CA INDEX NAME)



RN 205676-71-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-2-methyl-3-oxo-, methyl ester (CA INDEX NAME)



RN 205676-75-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 205676-76-2 CAPLUS
CN Butanedioic acid, [[2-[[[(1,1-dimethylethoxy)carbonyl](2,2,2-trifluoroethyl)amino]methyl]-4-methoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-77-3 CAPLUS
CN Butanedioic acid, [[4-methoxy-2-[[(2,2,2-trifluoroethyl)amino]methyl]phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 205676-78-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 205676-79-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205676-80-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205676-81-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205676-82-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205676-91-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[[4-(trifluoromethyl)phenyl]methoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205676-92-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205677-00-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-[[4-

(trifluoromethyl)phenyl]methyl]-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-01-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205677-02-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205677-03-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 205677-04-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 205677-16-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-methoxy-3-oxo-2-(2-phenylethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-17-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-hydroxy-3-oxo-2-(2-phenylethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-18-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-19-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 205677-20-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-nitro-1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-21-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4-amino-1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-22-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methoxy-1-

oxido-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-23-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methoxy-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-24-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-25-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-3-oxo-8-[3-(2-pyridinylamino)propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-26-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-28-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-(3-aminopropoxy)-2,3,4,5-tetrahydro-3-oxo-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 205677-27-6
CMF C16 H22 N2 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205677-29-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyrimidinylamino)propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-30-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-31-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[2-(1H-benzimidazol-2-yl)ethoxy]-2,3,4,5-tetrahydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-32-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-33-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-34-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4,6-dimethyl-1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-35-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4,6-dimethyl-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-36-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[2-(2-amino-4-thiazolyl)ethoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-37-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-8-[3-[(4-nitro-1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-38-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4-amino-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-39-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-nitro-1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-40-3 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4-amino-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-41-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-nitro-1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-42-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4-amino-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-43-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-8-[3-[[[(4-nitrophenyl)methoxy]carbonyl]amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-44-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-(3-aminopropoxy)-2,3,4,5-tetrahydro-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-45-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-2,3,4,5-tetrahydro-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-46-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-3-oxo-8-[3-[(4,5,6,7-tetrahydro-1H-1,3-diazepin-2-yl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-47-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methyl-1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-48-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methyl-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-49-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-50-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl](1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-51-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-52-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-8-[3-[methyl(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-53-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-2-methyl-8-[3-(methyl-2-pyridinylamino)propoxy]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-54-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl](1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-55-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-56-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 205677-57-2 CAPLUS
CN 2H-2-Benzazepine-2,4-diacetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl](1-oxido-2-pyridinyl)amino]propoxy]-1,3,4,5-tetrahydro-3-oxo-, α2-(1,1-dimethylethyl) α4-methyl ester (9CI) (CA INDEX NAME)



RN 205677-58-3 CAPLUS
CN 2H-2-Benzazepine-2,4-diacetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-1,3,4,5-tetrahydro-3-oxo-, α2-(1,1-dimethylethyl) α4-methyl ester (9CI) (CA INDEX NAME)



RN 205677-59-4 CAPLUS
CN 2H-2-Benzazepine-2,4-diacetic acid, 1,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-, α4-methyl ester (9CI) (CA INDEX NAME)



RN 205677-60-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl](1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-2-[(4-nitrophenyl)methyl]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-61-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-[(4-aminophenyl)methyl]-8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-62-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2-[(4-aminophenyl)methyl]-8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo- (9CI) (CA INDEX NAME)



RN 205677-63-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-64-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-65-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-(benzoyl-2-pyridinylamino)propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-66-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(3,3-dimethyl-1-oxobutyl)(1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-67-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[(3,3-dimethyl-1-oxobutyl)-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-68-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[[(2-methylpropoxy)carbonyl](1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-69-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[[(2-methylpropoxy)carbonyl]-2-pyridinylamino]propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-70-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl](1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-71-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl](1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-72-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-73-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl]-2-pyridinylamino]propoxy]-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-74-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[[[(4-nitrophenyl)methoxy]carbonyl]amino]propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 205677-75-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-(3-aminopropoxy)-2,3,4,5-tetrahydro-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-76-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyrimidinylamino)propoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-77-6 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propoxy]-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-78-7 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[methyl(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-79-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-(methyl-2-pyridinylamino)propoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 205677-80-1 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-81-2 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-82-3 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-83-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-8-[3-(2-pyridinylamino)propoxy]-2-(2,2,2-trifluoroethyl)-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-84-5 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methyl-1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-85-6 CAPLUS

CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(4-methyl-2-pyridinyl)amino]propoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-86-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-, methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-87-8 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-3-oxo-2-(2-phenylethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-88-9 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-3-oxo-2-(2-phenylethyl)-8-[3-(2-pyridinylamino)propoxy]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-89-0 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2-phenylethyl)-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205677-91-4 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 205676-89-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(oxotetrahydrobenzazepine compds. for vitronectin receptor antagonists)
RN 205676-89-7 CAPLUS
CN 1H-2-Benzazepine-4-acetic acid, 8-[3-[[(1,1-dimethylethoxy)carbonyl](1-oxido-2-pyridinyl)amino]propoxy]-2,3,4,5-tetrahydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1985:131794 CAPLUS Full-text
DN 102:131794
TI Total synthesis and study of biologically active lignans. III. Application of the α-hydroxyalkylation of β-benzyl γ-butyrolactones to the preparation of phenyltetralin and bisbenzocyclooctadiene skeletons. First synthesis of picrosteganes, formal synthesis of (±)-steganacin
AU Robin, Jean Pierre; Dhal, Robert; Brown, Eric
CS Lab. Synth. Org., Fac. Sci., Le Mans, 72017, Fr.
SO Tetrahedron (1984), 40(18), 3509-20
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA French
AB Kinetically controlled intramol. α-hydroxyalkylation of a suitable di-Ph aldehyde lactone gave dibenzocyclooctenolactones with a cis lactone-ring junction, such as (±)-picrostegane and (±)-isopicrostegane. Subsequent transformations led to the known (±)-isostegane. The chemical properties, the phys. data and biol. activity of these 3 diastereoisomers were compared with those of (±)-stegane, a 4th diastereoisomer obtained by hydrogenolysis of synthetic (±)-steganacin.
IT 65171-08-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 65171-08-6 CAPLUS
CN Butanedioic acid, [[2-(6-cyano-1,3-benzodioxol-5-yl)-3,4,5-trimethoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



IT 65171-03-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with bis(trifluoroacetyl)hydroxylamine)
RN 65171-03-1 CAPLUS
CN Butanedioic acid, [[2-(6-formyl-1,3-benzodioxol-5-yl)-3,4,5-trimethoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



L11 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1984:34317 CAPLUS Full-text
DN 100:34317
TI Total synthesis and study of biologically active lignans. Application of the α-hydroxyalkylation of β-benzyl-γ-butyrolactones to the preparation of phenyltetralin and bisbenzocyclooctadiene skeletons. 4. Total synthesis of (±)-steganone and its congeners and synthesis of (±)-stegane
AU Dhal, Robert; Brown, Eric; Robin, Jean Pierre
CS Lab. Synth. Org., Fac. Sci., le Mans, 72017, Fr.
SO Tetrahedron (1983), 39(17), 2787-94
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA French
GI



I



II



III

AB The biphenyl I was cyclized by intramol. hydroxyalkylation to the isomeric alcs. II. These were oxidized using Jones' reagents, to afford the enol together with the β-oxo lactone. Decarboxylation of this mixture using Ba(OH)2, followed by Jones' oxidation gave the isomeric γ-oxo acids which were converted to (±)-steganone (III) using Raphael's method, in an overall yield of 20.7% from the I.
IT 88348-33-8
RL: RCT (Reactant); RACT (Reactant or reagent)(cyclization of)
RN 88348-33-8 CAPLUS
CN Butanedioic acid, [[2-(1,3-benzodioxol-5-yl)-3,4,5-trimethoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



L11 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1983:106906 CAPLUS Full-text
DN 98:106906
TI Total syntheses and studies of biologically active lignans. I. Application of the Ullmann reaction to the preparation of biaryl precursors of bisbenzocyclooctadiene lignans
AU Brown, Eric; Robin, Jean Pierre; Dhal, Robert
CS Lab. Syn. Org., Fac. Sci., Le Mans, 72017, Fr.
SO Tetrahedron (1982), 38(16), 2569-79
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA French
GI



I



II

AB A number of biaryls, with reactive functional groups in the ortho positions, were prepared in ≤88% yield by the Ullmann reaction. E.g., treatment of 2,3,4,5-Br(MeO)3C6HCHO with I in the presence of Cu powder at 210° for 20 min gave 70% II. These biaryls are possible synthons for bisbenzocyclooctadiene lignans such as schizandrin and steganacin.

IT 65171-02-0P 65171-03-1P 84798-99-2P
84799-00-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 65171-02-0 CAPLUS
CN Butanedioic acid, [(6'-formyl-2',3',4,4',5,6-hexamethoxy[1,1'-biphenyl]-2-yl)methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 65171-03-1 CAPLUS
CN Butanedioic acid, [[2-(6-formyl-1,3-benzodioxol-5-yl)-3,4,5-trimethoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 84798-99-2 CAPLUS
CN Butanedioic acid, [[3,4,5-trimethoxy-2-[6-(methoxycarbonyl)-1,3-benzodioxol-5-yl]phenyl]methyl]-, dimethyl ester, stereoisomer (9CI) (CA INDEX NAME)



RN 84799-00-8 CAPLUS
CN Butanedioic acid, [[3,4,5-trimethoxy-2-[6-(methoxycarbonyl)-1,3-benzodioxol-5-yl]phenyl]methyl]-, dimethyl ester, stereoisomer (9CI) (CA INDEX NAME)



L11 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1978:22291 CAPLUS Full-text
DN 88:22291
TI Application of the Ullmann reaction to the synthesis of bulky diaryls, precursors of bisbenzocyclooctadiene lignans
AU Brown, Eric; Robin, Jean Pierre
CS Lab. Syn. Org., Fac. Sci., Le Mans, Fr.
SO Tetrahedron Letters (1977), (23), 2015-18
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA French
GI



I



II

AB The biphenyl derivs. I [R = CHO, CO2Me, CN, R1 = CH2CH(CO2Me)CH2CO2Me; R = CO2Me, R1 = CHO, CH:C(CO2Me)CH2CO2Me; R = R1 = CHO], potential precursors of steganone and related compds., and II [R = CHO, CH2CH(CO2Me)CH2CO2Me, 5-oxotetrahydrofur-3-ylmethyl], potential precursors of schizandrine and analogs, were prepared, mainly by Ullmann reactions. E.g., 2,3,4,5-Br(MeO)3C6HCHO with 2,3,4,5-I(MeO)3C6HCH2CH(CO2Me)CH2CO2Me and powdered Cu at 230° for 0.5 h gave 55% II [R = CH2CH(CO2Me)CH2CO2Me].

IT 65171-02-0P 65171-03-1P 65171-06-4P
65171-08-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 65171-02-0 CAPLUS
CN Butanedioic acid, [(6'-formyl-2',3',4,4',5,6-hexamethoxy[1,1'-biphenyl]-2-yl)methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 65171-03-1 CAPLUS
CN Butanedioic acid, [[2-(6-formyl-1,3-benzodioxol-5-yl)-3,4,5-trimethoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 65171-06-4 CAPLUS
CN Butanedioic acid, [[3,4,5-trimethoxy-2-[6-(methoxycarbonyl)-1,3-benzodioxol-5-yl]phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 65171-08-6 CAPLUS
CN Butanedioic acid, [[2-(6-cyano-1,3-benzodioxol-5-yl)-3,4,5-trimethoxyphenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



L11 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1977:90170 CAPLUS Full-text
DN 86:90170
TI Valonia tannins. V. Trilloic acid, a new phenolic acid from valonia tannins
AU Mayer, Walter; Busath, Harald; Schick, Hartmut
CS Org.-Chem. Inst., Univ. Heidelberg, Heidelberg, Fed. Rep. Ger.
SO Justus Liebigs Annalen der Chemie (1976), (12), 2169-77
CODEN: JLACBF; ISSN: 0075-4617
DT Journal
LA German
GI For diagram(s), see printed CA Issue.
AB Valolaginic acid (I), a Valonia tannin whose structure was proposed previously (W. Mayer, et al., 1976), yielded on acid hydrolysis ellagic acid and a crystalline compound, trilloic acid trilactone (II). The structures of II and its free acid, named trilloic acid (III), were determined The acetylated and methylated derivs. of II were prepared These II derivs. contained an ellagic acid portion linked by C-C bonding with the γ-lactone of a γ-carboxy-α-hydroxyadipic acid. Further 1H NMR studies showed the position of this linkage. The structure of the trilloic acid boundin I was thus determined, and the proposed structure for I was confirmed.
IT 61954-98-1
RL: PROC (Process)
(of Valonia, structure determination of)
RN 61954-98-1 CAPLUS
CN 1,2,4-Butanetricarboxylic acid, 3-(2,6'-dicarboxy-2',3',4,4',5,6-hexahydroxy[1,1'-biphenyl]-3-yl)-4-hydroxy- (9CI) (CA INDEX NAME)



L11 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1973:159298 CAPLUS Full-text
DN 78:159298
TI Synthesis of 1-methyl-3-methoxy-7-isopropylnaphthalene
AU Adachi, Kazuo
CS Osaka Inst. Technol., Osaka, Japan
SO Yuki Gosei Kagaku Kyokaishi (1973), 31(2), 166-70
CODEN: YGKKAE; ISSN: 0037-9980
DT Journal
LA Japanese
GI For diagram(s), see printed CA Issue.
AB The title compound (I) was prepared from m-cresol. Thus, the Grignard reagent of 4-bromo-3-methylanisole was treated with HCHO, condensed with tri-Et ethane-1,1,2-tricarboxylate, hydrolyzed, and decarboxylated to give 81% 2-(4-methoxy-2-methylphenyl)-succinic acid (II). II was refluxed with P2O2 in C6H6 to give 97% 2-(4-methoxy-2-methylbenzyl)succinic acid anhydride (III). The Friedel-Crafts reaction of III in PhNO2-AlCl3 gave 91% 7-methoxy-5-methyl-1-oxo-1,2,3,4-tetrahydronaphthalene-3-carboxylic acid (IV).' Me 6-methoxy-8-methyl-1,2,3,4-tetrahydronaphthalene-2- carboxylate, obtained by the reduction of IV, was treated with MeMgI and decomposed with NH4Cl to give 94% 6-methoxy-8-methyl-2-(1-hydroxy-1- methylethyl)-1,2,3,4-tetrahydronaphthalene (V). V was heated with S to give 59% I.
IT 41499-85-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41499-85-8 CAPLUS
CN Butanedioic acid, [(4-methoxy-2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



```
=> d l2; d l7; d his; log y
L2 HAS NO ANSWERS
L1                STR
```



```
Structure attributes must be viewed using STN Express query preparation.
L2                QUE  ABB=ON  PLU=ON  L1

L7 HAS NO ANSWERS
L6                STR
```



```
Structure attributes must be viewed using STN Express query preparation.
L7                QUE  ABB=ON  PLU=ON  L6
     (FILE 'HOME' ENTERED AT 14:13:57 ON 11 AUG 2007)
     FILE 'REGISTRY' ENTERED AT 14:14:17 ON 11 AUG 2007
L1                STRUCTURE UPLOADED
L2                QUE L1
L3              1 S L2
L4             28 S L2 FUL
     FILE 'CAPLUS' ENTERED AT 14:14:48 ON 11 AUG 2007
L5             15 S L4
     FILE 'STNGUIDE' ENTERED AT 14:14:56 ON 11 AUG 2007
     FILE 'REGISTRY' ENTERED AT 14:16:34 ON 11 AUG 2007
L6                STRUCTURE UPLOADED
L7                QUE L6
L8              8 S L7
L9            191 S L7 FUL
     FILE 'CAPLUS' ENTERED AT 14:18:12 ON 11 AUG 2007
L10            29 S L9
L11            36 S L5 OR L10
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                           191.13     708.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                              ENTRY    SESSION
CA SUBSCRIBER PRICE                           -28.08     -28.08

STN INTERNATIONAL LOGOFF AT 14:19:51 ON 11 AUG 2007
```